The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Immune Checkpoint Inhibitors & Immune-Related Adverse Events

Immune Checkpoint Inhibitors & Immune-Related Adverse Events

September 20, 2018 • By Priya Chokshi, MD, Roberta Seidman, MD, Noah Levit, PhD, MD, & Steven E. Carsons, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF
Figure 2: Left Quadriceps Muscle Biopsy

Figure 2: Left Quadriceps Muscle Biopsy
A: Two necrotic myofibers with pale sarcoplasm are identified by arrows in this area of a paraffin hematoxylin and eosin (H&E) section, which also exhibits very mild endomysial lymphocytic inflammation.
B: A mild perimysial perivascular lymphocytic inflammatory infiltrate is present in this region of a paraffin H&E section.
C: Arrows indicate two regenerating myofibers, which are identified by their basophilic cytoplasm and large nuclei with nucleoli, and a small number of lymphocytes infiltrate this zone (paraffin H&E). Inflammation associated with necrotic or regenerating myofibers may be a reactive change rather than evidence of an inflammatory myopathy; the perivascular inflammation provides more convincing evidence of an immune-mediated myopathy.
D: A low-power view of a portion of a cryostat H&E section illustrates that much of the biopsy has no inflammation and no myofiber necrosis or regeneration.
E: Human leucocyte antigen Class ABC or Class I (HLA Class I) immunohistochemistry exhibits labeling of many myofibers, indicated by the brown staining. In this area, there is a somewhat perifascicular concentration of positive myofibers.
F: HLA Class I immunohistochemistry shows strong surface labeling and sarcoplasmic staining of all of the myofibers in this area. Original magnifications: A, B, C—400x; D, E—100x; F—200x

The constellation of findings, temporal association of events and presence of multi-organ involvement raised suspicion for an immunotherapy-mediated toxicity. The patient was started on 1 mg/kg of methylprednisolone immediately after the muscle biopsy. The choice of steroid dosing was based on guidelines for management of the known toxicities of nivolumab (skin, pneumonitis, neurologic) because no guidelines on the management of myositis or cardiotoxicity secondary to nivolumab therapy were known to have been published at the time.

You Might Also Like
  • Immune-Related Adverse Events with Use of Checkpoint Inhibitors for Immunotherapy of Cancer
  • The Immune Checkpoint Inhibitors Unleashed to Fight Cancer
  • Study Assesses Immune Checkpoint Inhibitors Safety in Rheumatic Disease
Explore This Issue
September 2018

Within two days of starting steroids, the patient demonstrated improvement in her respiratory status and stridor. On Day 3, she was able to sit up without assistance. By Day 7, her dysphagia and dysphonia were significantly improved, and the nasogastric tube was removed. Her dyspnea also improved, and the patient no longer required oxygen for relief. An ultrasound of the diaphragm following the steroid treatment showed appropriate movement with respiration. Her ptosis resolved, and the rash gradually diminished in intensity and size.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

By the time of discharge three weeks later, the patient was again able to walk, albeit a few steps. Her lab values had normalized: CK of 126 IU/L, troponin of 0.3 ng/mL, ALT of 95 u/L and AST of 32 u/L. She was discharged to rehab with an oral prednisone taper.

Pages: 1 2 3 4 5 6 7 8 9 10 | Single Page

Filed Under: Conditions, Drug Updates, Systemic Inflammatory Syndromes Tagged With: immune-related adverse events, irAEs, myositis, nivolumabIssue: September 2018

You Might Also Like:
  • Immune-Related Adverse Events with Use of Checkpoint Inhibitors for Immunotherapy of Cancer
  • The Immune Checkpoint Inhibitors Unleashed to Fight Cancer
  • Study Assesses Immune Checkpoint Inhibitors Safety in Rheumatic Disease
  • Rheumatology Case Report: Immune-Related Aortitis Associated with Ipilimumab

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)